The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

Genetic medicines-focused Scribe Therapeutics is racing toward the clinic on the heels of a preclinical data drop for three ...

Crispr Therapeutics (CRSP) quickly rose 1.3% amid some takeover speculation. Crispr (CRSP) is said to have attracted takeover interest, according to traders, who cited a Betaville "uncooked' alert ...

Study shows gene editing restores drug sensitivity by targeting NRF2, with potential across multiple tumor types.

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

Outcomes validate the company’s PTAP platform as a foundation for a rapid, adaptable antiviral modality across animal and ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...

The colonies of Escherichia coli sitting in this petri dish become pathogenic when they carry Shiga toxin genes. Credit: Shutterstock “We’re essentially converting a pathogenic strain into a ...

CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company ...